Clinical & Translational Metabolism:

ME/CFS and Long COVID Demonstrate Similar Bioenergetic Impairment and Recovery Failure on Two-Day Cardiopulmonary Exercise Testing

 

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is common in people with Long COVID, including post-exertional malaise (PEM). The overlapping observation of PEM in pre- and post-COVID forms of ME/CFS suggests the potential for shared bioenergetic impairments, but this has not yet been demonstrated. Two cardiopulmonary exercise tests (CPET) administered 24 h apart can elucidate the metabolic underpinnings of each disease. This retrospective study examined physiological responses during two-day CPET in people with ME/CFS (63 females/21 males), Long COVID (52 females/27 males), and matched non-disabled control participants (51 females/20 males). Data were analyzed within sexes using repeated measures analysis of variance. All participants met maximal effort criteria. There were significant reductions in oxygen consumption (O₂) and workload at the ventilatory anaerobic threshold (VAT) in both patient groups compared to non-disabled controls, with larger effect sizes at VAT than at peak exertion. Performance decrements were observed in both sexes. Females exhibited more pronounced abnormalities and significant group by test effects. No significant differences were observed between patient groups. Severe disability based on impaired O₂ was prevalent in both patient groups. Hemodynamic and ventilatory measures were within normal ranges. ME/CFS and Long COVID both involve a functionally significant bioenergetic failure complicated by inadequate post-exertional recovery, which is similar between the conditions and unexplained by hemodynamic and ventilatory changes. Findings support the utility of two-day CPET as an objective measure functional impairment in ME/CFS. Future studies may integrate mechanistic biomarkers with two-day CPET as trial endpoints and to establish likely responses to treatments for PEM.


Chronic disease following an initial illness is a well-recognized and longstanding public health issue [1]. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem disease present in approximately 1.4% of the global population [2]. It is characterized by a profound suffering compared to other major chronic non-communicable health conditions [3], which often results in a high degree of loss and burden [4,5,6]. Long COVID, also known as Post-COVID Condition [7, 8], has emerged as a highly prevalent and persistent sequel to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [9]. It is broadly defined as symptoms persisting at least 3 months following confirmed or suspected SARS-CoV-2 infection and lasting at least 2 months without an alternative explanation [7, 8]. It may affect approximately up to 34–38% of infected cases [9] with economic losses estimated at 1% of global gross domestic product [10]. The disability and loss associated with ME/CFS and Long COVID place a premium on understanding their complex pathophysiology to develop effective tests and treatments.


Post-exertional malaise (PEM) is central to the diagnosis of ME/CFS [11, 12] and it is prevalent in Long COVID [13,14,15,16]. PEM involves a delayed and disproportionate exacerbation of unusual symptoms and signs in response to primarily physical (e.g., chronotropic and orthostatic), cognitive, and environmental forms of exertion [12]. Contemporary case definition criteria for ME/CFS require PEM for the diagnosis [11, 12, 17, 18], characterizing unusual timing, disproportional response to exertion, and extended and often incomplete recovery as key elements [11, 12]. Converging evidence indicates a substantial subset of individuals with Long COVID meet diagnostic criteria for ME/CFS [19]. As a result of this overlap, national expert consensus recommends evaluating people with Long COVID for ME/CFS when PEM may be present [7].


Cardiopulmonary exercise testing (CPET) offers an integrative objective assessment of systems-level responses to physical exertion [20]. In ME/CFS research, two-day CPET testing already has emerged as a valid and reliable assessment of post-exertional physiology [21, 22]. This is important because the hallmark of PEM is unusual symptoms and signs from an initial exertion. Two-day CPET involves two CPETs administered 24 h apart. The first CPET is an evaluation of baseline physiological functioning, as well as a patient/participant-referenced exercise stressor [21]. The second CPET is then positioned to measure physiological responses in the post-exertional state [21]. Two-day CPET studies in ME/CFS consistently demonstrate performance decrements on the second test at the ventilatory anaerobic threshold (VAT) that distinguish people living with ME/CFS from sedentary control participants [21, 22].


The early body of two-day CPET studies in Long COVID has yielded mixed results. One larger study revealed performance decrements in volume of oxygen (O₂) consumed and workload at the ventilatory anaerobic threshold [23], while a smaller study demonstrated null results [24]. Direct, sex-stratified comparisons of two-day CPET responses have not yet been completed. In addition, a comparison of responses across people living with Long COVID, ME/CFS, and non-disabled matched controls would assist in understanding physiological similarities and differences in individuals expressing PEM as compared to normal post-exercise recovery. Therefore, the purpose of this study was to evaluate two-day CPET responses at VAT and maximal exertion in people living with Long COVID, ME/CFS, and non-disabled matched controls. Based on the prior observations of PEM in both groups, we hypothesized that people living with ME/CFS and people living with Long COVID would objectively demonstrate similar metabolic signatures corresponding to a shared bioenergetic pathophysiology.



 

Donate with Confidence

A Fiscally Sponsored Program of United Charitable, a registered 501(c)3 nonprofit organization #20-4286082.


 

Workwell Foundation | P.O. Box 1435 | Ripon, CA 95366 US

Bluesky  X  Facebook